Contact information
Eileen Parkes
MB BCh, Ba(O) (Hons), MRCP (Onc), PhD
ASSOCIATE PROFESSOR, INNATE TUMOUR IMMUNOLOGY, Group leader
- Consultant Medical Oncologist, Early Phase Trials
RESEARCH SUMMARY
- Understand resistance mechanisms to immune-targeting treatments in cancer;
- Characterise the role of the interaction of chromosomal instability and DNA repair deficiency with immune activation in tumour initiation, progression and response.
- Study tumour microenvironment, fibroblasts and extracellular matrix in chromosomally unstable cancers.
In the Parkes Lab we study intrinsic inflammatory pathways in cancer. These are important immune pathways, present in all cells, that act as emergency response pathways to viral infection. However, in cancer, these pathways can be rewired and hijacked by the tumour to promote growth, invasion and metastasis.
Recent publications
-
Nanotechnology for immuno-oncology.
Journal article
Grippin AJ. et al, (2025), Nature cancer
-
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.
Preprint
Beernaert B. et al, (2025)
-
CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.
Journal article
Skolariki A. et al, (2025), Mol Oncol
-
Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.
Journal article
Vadibeler S. et al, (2025), Matrix biology : journal of the International Society for Matrix Biology
-
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Preprint
Lawson NM. et al, (2025)